In clinical and commercial viral vector production, the robustness, scalability, and efficiency of upstream processes critically influence titer, product quality, and cost of goods (COGs). Leveraging proven project experience, CoJourney has developed core optimization strategies to accelerate process understanding, streamline lockdowns, and ensure successful scale-up.
- Risk-Forward Strategy for Process Scale-Up
- Early bottleneck identification: Develop robust scale-down models to proactively assess risks (e.g., transfection mixture transfer, mixing dynamics).
- Unit operation optimization: Independently refine critical steps (cell culture, transfection, harvest) before integrating into a seamless workflow.
Success Criteria for Scale-Up:
Predictability: Scale-down model must reliably translate to large-scale production. Controllability: Key parameters (e.g., pH, DO, cell density) are monitored and adjusted in real time. Scalability: The process delivers consistent results across scales.
- Optimizing Suspension Culture Systems
Compared to adherent platforms, suspension culture enhances scalability and batch consistency. Key bioreactor parameters—cell density, feeding strategy, and transfection efficiency—are optimized to ensure reproducible large-scale production.
- Transfection Process Optimization & Controls
Transfection efficiency hinges on:
- Cell density at transfection
- Plasmid DNA ratios
- Transfection reagent to DNA ratio
- Mixing dynamics for homogeneity
Structured DoE (Design of Experiments) approaches ensure robustness and scalability.
- Harvest Strategies
For large-scale production, high recovery harvest steps using depth filtration are optimized to balance:
- Impurity removal (e.g., endonuclease treatment)
- Cost efficiency (e.g., choice of endonuclease)
- Process time
- Recovery
Integrated Upstream-Downstream Optimization
At CoJourney, upstream processes are tuned to align with Critical Quality Attributes (CQAs), including:
- Titer and full/empty capsid ratio
- Residual host cell DNA/proteins
- Infectious titer-to-vg titer ratio
This integration reduces downstream burdens and improves overall yield.
Results: Proven Success in AAV Production
By implementing these strategies across multiple AAV projects, CoJourney has achieved:
✅ >90% process transfer success rate
✅ 3–8x higher rAAV yields (vs. industry averages)
✅ >70% batch cost reduction
✅ Single-dose cost reduced by >10x
Recommendations for Future Improvements
- Adopt QbD (Quality by Design) early: Define design spaces to enhance process robustness.
- Leverage emerging technologies: Explore novel media supplements, transfection enhancers, and high-throughput screening to maintain a competitive advantage.
